HATS: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==HATS Trial== ===Objective=== To assess the effects of lipid-lowering drugs and/or antioxidant vitamins on progression or regr..." |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Objective== | |||
To assess the effects of lipid-lowering drugs and/or antioxidant vitamins on progression or regression of coronary heart disease as measured by quantitative angiography in patients with low high density lipoprotein (HDL) cholesterol. | To assess the effects of lipid-lowering drugs and/or antioxidant vitamins on progression or regression of coronary heart disease as measured by quantitative angiography in patients with low high density lipoprotein (HDL) cholesterol. | ||
==Methods== | |||
HDL-Atherosclerosis Treatment Study (HATS) was a randomized, 2 x 2 factorial study wherein 160 patients, both men and women with low HDL cholesterol, with at least one 50% stenotic coronary lesion or three 30% stenotic coronary lesions were enrolled. All the patients were randomized into four groups which were [[simvastatin]] (10-20g/day) plus [[niacin]] (2-4g/day), antioxidant vitamins (vitamins E, C, A and selenium), simvastatin-niacin plus [[antioxidant]]s; or placebos. The primary end points were arteriographic evidence of a change in coronary stenosis and the occurrence of a first cardiovascular event (death, myocardial infarction, stroke, or revascularization). Coronary angiograms were done at baseline and at three years to assess the change. | HDL-Atherosclerosis Treatment Study (HATS) was a randomized, 2 x 2 factorial study wherein 160 patients, both men and women with low HDL cholesterol, with at least one 50% stenotic coronary lesion or three 30% stenotic coronary lesions were enrolled. All the patients were randomized into four groups which were [[simvastatin]] (10-20g/day) plus [[niacin]] (2-4g/day), antioxidant vitamins (vitamins E, C, A and selenium), simvastatin-niacin plus [[antioxidant]]s; or placebos. The primary end points were arteriographic evidence of a change in coronary stenosis and the occurrence of a first cardiovascular event (death, myocardial infarction, stroke, or revascularization). Coronary angiograms were done at baseline and at three years to assess the change. | ||
==Results== | |||
* In the simvastatin-niacin group mean LDL-C was reduced by 42% and mean HDL-C was increased by 26% while levels of LDL-C and HDL-C in the antioxidants and placebo groups remained unaltered. | * In the simvastatin-niacin group mean LDL-C was reduced by 42% and mean HDL-C was increased by 26% while levels of LDL-C and HDL-C in the antioxidants and placebo groups remained unaltered. | ||
* The rate of progression of coronary stenoses was lower in the simvastatin-niacin group compared to the other groups. | * The rate of progression of coronary stenoses was lower in the simvastatin-niacin group compared to the other groups. | ||
| Line 16: | Line 15: | ||
* Antioxidant vitamins alone had no benefit on progression or on clinical events. | * Antioxidant vitamins alone had no benefit on progression or on clinical events. | ||
==Conclusion== | |||
Addition of a drug that increases HDL-C levels to a [[statin]] proves to have additional protection over just statin alone.<ref name="pmid11757504">{{cite journal |author=Brown BG, Zhao XQ, Chait A, ''et al.'' |title=Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease |journal=[[The New England Journal of Medicine]] |volume=345 |issue=22 |pages=1583–92 |year=2001 |month=November |pmid=11757504 |doi=10.1056/NEJMoa011090 |url=}}</ref> | Addition of a drug that increases HDL-C levels to a [[statin]] proves to have additional protection over just statin alone.<ref name="pmid11757504">{{cite journal |author=Brown BG, Zhao XQ, Chait A, ''et al.'' |title=Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease |journal=[[The New England Journal of Medicine]] |volume=345 |issue=22 |pages=1583–92 |year=2001 |month=November |pmid=11757504 |doi=10.1056/NEJMoa011090 |url=}}</ref> | ||
| Line 25: | Line 24: | ||
[[Category:Lipopedia]] | [[Category:Lipopedia]] | ||
[[Category:HDL]] | [[Category:HDL]] | ||
[[Category:Clinical trials]] | |||
Revision as of 23:18, 17 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
HATS On the Web |
|
American Roentgen Ray Society Images of HATS |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To assess the effects of lipid-lowering drugs and/or antioxidant vitamins on progression or regression of coronary heart disease as measured by quantitative angiography in patients with low high density lipoprotein (HDL) cholesterol.
Methods
HDL-Atherosclerosis Treatment Study (HATS) was a randomized, 2 x 2 factorial study wherein 160 patients, both men and women with low HDL cholesterol, with at least one 50% stenotic coronary lesion or three 30% stenotic coronary lesions were enrolled. All the patients were randomized into four groups which were simvastatin (10-20g/day) plus niacin (2-4g/day), antioxidant vitamins (vitamins E, C, A and selenium), simvastatin-niacin plus antioxidants; or placebos. The primary end points were arteriographic evidence of a change in coronary stenosis and the occurrence of a first cardiovascular event (death, myocardial infarction, stroke, or revascularization). Coronary angiograms were done at baseline and at three years to assess the change.
Results
- In the simvastatin-niacin group mean LDL-C was reduced by 42% and mean HDL-C was increased by 26% while levels of LDL-C and HDL-C in the antioxidants and placebo groups remained unaltered.
- The rate of progression of coronary stenoses was lower in the simvastatin-niacin group compared to the other groups.
- Patients receiving simvastatin and niacin sustained lower cardiovascular events.
- Antioxidant vitamins alone had no benefit on progression or on clinical events.
Conclusion
Addition of a drug that increases HDL-C levels to a statin proves to have additional protection over just statin alone.[1]
References
- ↑ Brown BG, Zhao XQ, Chait A; et al. (2001). "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease". The New England Journal of Medicine. 345 (22): 1583–92. doi:10.1056/NEJMoa011090. PMID 11757504. Unknown parameter
|month=ignored (help)